Introduction {#s1}
============

The Hippo pathway plays an important role in cell proliferation, organ size control, and cancer development and progression [@pone.0054211-Chan1], [@pone.0054211-Zhao1], [@pone.0054211-Pan1], [@pone.0054211-Harvey1]. YAP and TAZ are both transcriptional co-activators that are inhibited by the Hippo pathway [@pone.0054211-Chan1], [@pone.0054211-Zhao1], [@pone.0054211-Pan1], [@pone.0054211-Harvey1]. Aberrant inactivation of the Hippo pathway and/or overexpression of TAZ and YAP results in transcriptional activation of their downstream targets [@pone.0054211-Chan1], [@pone.0054211-Zhao1], [@pone.0054211-Pan1], [@pone.0054211-Harvey1].

YAP overexpression induces cell proliferation and epithelial mesenchymal transition (EMT), and inhibits apoptosis and contact inhibition [@pone.0054211-Overholtzer1], [@pone.0054211-Zhao2], [@pone.0054211-Zhang1]. Transcriptional activation of epidermal growth factor receptor ligand amphiregulin may account for YAP-mediated induction of cell proliferation, especially under serum-depletion [@pone.0054211-Zhang1], while YAP also cooperates with Myc to promote cell proliferation [@pone.0054211-NetoSilva1]. Recently, YAP has been shown to play a critical role in stem cell biology. It is induced during pluripotent stem cell reprogramming, whilst silencing of YAP reduces the pluripotency of embryonic stem cells [@pone.0054211-Lian1]. YAP promotes ovarian cancer progression, and high levels of nuclear expression are inversely associated with patient survival [@pone.0054211-Hall1]. In particular, YAP is associated with clear cell ovarian tumors, an ovarian malignancy subtype with poor prognosis [@pone.0054211-Zhang2]. YAP has also been shown to play an oncogenic role in esophageal squamous cell carcinoma [@pone.0054211-Muramatsu1]. In liver cancer, microRNA-mediated inhibition of YAP inhibits tumor characteristics including cell proliferation and invasion [@pone.0054211-Liu1]. Conversely, there are reports showing an opposite, tumor suppressive, role of YAP in promoting p73-mediated apoptosis [@pone.0054211-Yuan1], [@pone.0054211-Basu1]. In breast and head and neck cancers, YAP has been shown to act as a tumor suppressor in certain circumstances [@pone.0054211-Yuan1], [@pone.0054211-Ehsanian1].

TAZ is structurally homologous to YAP, is likewise inhibited by the Hippo pathway, and also promotes EMT-mediated cancer progression [@pone.0054211-Lei1], [@pone.0054211-Chan2], [@pone.0054211-Zhang3]. TAZ regulates mesenchymal stem cell differentiation by modulating Runx2- and PPARgamma-dependent gene expression [@pone.0054211-Hong1], as well as stem cell self-renewal through controlling localization of Smad [@pone.0054211-Varelas1]. TAZ plays an important role in the progression of breast [@pone.0054211-Zhao3], [@pone.0054211-Lai1] and non-small cell lung cancer [@pone.0054211-Zhou1], [@pone.0054211-Xie1]. Importantly, TAZ confers cancer stem cell-related traits on breast cancer cells, further highlighting its importance in tumor initiation and progression [@pone.0054211-Cordenonsi1]. TAZ is also overexpressed in papillary thyroid carcinoma [@pone.0054211-deCristofaro1].

TAZ and YAP have been shown to interact with several transcriptional factors [@pone.0054211-Zhao1], [@pone.0054211-Pan1], [@pone.0054211-Harvey1], with the TEAD family of transcriptional factors (TEAD1-4) being the most relevant in cell proliferation and cancer progression [@pone.0054211-Zhang3], [@pone.0054211-Chan3], [@pone.0054211-Zhao4]. The X-ray crystal structures of YAP-TEAD complexes have been resolved and the proposed interaction is supported by and consistent with functional analysis [@pone.0054211-Chen1], [@pone.0054211-Li1], [@pone.0054211-Tian1], showing that YAP-TEAD complexes activates gene transcription.

YAP expression was observed in colon adenocarcinoma [@pone.0054211-Steinhardt1], [@pone.0054211-Konsavage1], [@pone.0054211-Avruch1]. It is overexpressed in human colon cancer specimens and overexpression of YAP promotes cell proliferation and survival in colon cancer cells [@pone.0054211-Zhou2]. Recent findings show that knockdown of TAZ results in a decrease in cell proliferation in culture and tumor growth *in vivo* [@pone.0054211-Cordenonsi1].

Despite evidence suggesting the potential implication of YAP and TAZ in colon cancer progression, their prognostic significance in colorectal cancer is unknown. In this study, we analyzed the mRNA expression of YAP and TAZ, and two of its downstream target genes, *AXL* and *CTGF*, in two independent colon cancer patient cohorts comprising 522 patients. We found that TAZ, but not YAP, is a prognostic marker in colon cancer progression. Furthermore, TAZ-*AXL-CTGF* co-overexpression, which defines both the expression of TAZ and its transcriptional activity on target gene expression, is a novel prognostic indicator, that is independent of tumor grade and stage, for colon cancer patients. The role of TAZ in colon cancer cell proliferation and oncogenesis was validated by functional study.

Materials and Methods {#s2}
=====================

Extraction of clinical and microarray gene expression data from colon cancer patient datasets {#s2a}
---------------------------------------------------------------------------------------------

Two colon cancer patient datasets, GSE14333 [@pone.0054211-Jorissen1] and GSE17538 [@pone.0054211-Smith1], available in the Gene Expression Omnibus (GEO) Database (<http://www.ncbi.nlm.nih.gov/gds>) were included in this study. The GEO website has standardized URLs for its individual datasets, e.g. the overall summary information about the microarray dataset GSE14333 can be accessed at <http://www.ncbi.nlm.gov/geo/query/acc.cgi?acc=GSE14333>. For each GEO data series, links are provided at the bottom of the page to the Series Matrix File(s), which contain the expression values for each gene (probeset) and each microarray. The URLs to the Series Matrix File(s) are also standardized. For GSE14333, the URL was <ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/SeriesMatrix/GSE14333>. The files in gzip format were then unzipped to the tab-delimited text format, which contain detailed information for statistical analysis. The GSE14333 and GSE17538 datasets are the two largest colon cancer patient datasets on the database, and comprise 522 patients, 458 of whose survival data is available in the database. The GSE17538 data series consists of four SubSeries: GSE17536, GSE17537, GSE19072 and GSE19073. GSE19072 and GSE19073 were excluded from this study as they lack clinical data. Microarray gene expression data were retrieved from the data matrices deposited to the GEO database by the original authors. The gene expression levels in GSE14333 and GSE17538 are represented by base-2 logarithm of the MAS5 value and the RMA values, respectively, as adopted by the original authors. R scripting was used to extract the expression values of a small number of genes (probesets) of interest and the clinical data from the data matrixes downloaded from GEO.

Demographic and clinical data of the two patient cohorts {#s2b}
--------------------------------------------------------

Both age and gender of the patients were available demographic data in the two datasets analyzed in the present study. Patients had a median age of 67 years (Range: 26--92 year-old) and 65.5 years (Range: 23--94 year-old) in GSE14333 and GSE17538, respectively. There were 43% and 46% female, respectively, in cohort GSE14333 and GSE17538. The GSE14333 cohort consists of 290 patients, for whom 226 survival data were available. Fifteen, 32, 31 and 21% of patients had stage A, B, C and D tumors, respectively. The survival data were not available for all the patients of stage D. Survival data were available for all 232 patients in the GSE17538 cohort. Twelve, 31, 33 and 24% patients had tumors of AJCC stage I, II, III and IV, respectively, and 8, 78 and 14% of patients had Grade A, B and C tumors respectively.

Correlations of gene expression levels and clinical data {#s2c}
--------------------------------------------------------

All statistical analyses were performed using SPSS19.0. The associations between expression levels of genes were analyzed by Spearman\'s rank test. Expression levels were further divided into high and low levels using median expression level as the cut-off point for Kaplan-Meier survival analysis. Results were compared by log-rank test. Univeriate Cox regression analysis was used to correlate the gene expression levels and patient survival and multivariate Cox regression analysis was used to identify independent predictors for patient survival using a backward stepwise approach with an entry limit of p\<0.1 and a removal limit of p\>0.05. Patients were divided further into 4 groups based on the expression levels of TAZ, AXL and CTGF; the TAZ-AXL-CTGF-low group consisted of patients who expressed all these 3 genes at low levels; the TAZ-AXL-CTGF-intermediate-low group consisted of patients who expressed one of these three genes at a high level; the TAZ-AXL-CTGF-intermediate-high group consisted of patients who expressed two of these three genes at high levels; the TAZ-AXL-CTGF-high group consisted of patients who expressed all three genes at high levels. The survival time of patients stratified by this grouping method were analyzed by Kaplan-Meier analysis and Cox regression as described above.

Identification of TAZ-AXL-CTGF co-expressing genes {#s2d}
--------------------------------------------------

Patients were stratified into four groups based on the expression levels of TAZ, AXL and CTGF as described above. The gene expression patterns of patients in TAZ-AXL-CTGF low subgroup and those in the TAZ-AXL-CTGF high subgroup (whose survival was significantly poorer) were compared. Probesets that were differentially expressed between these two subgroups were identified by 2-sample Welch\'s T-test. This test was used to avoid the type I error due to unequal variances of the values of probesets between subgroups. Briefly, a Welch\'s t test was applied to each probeset corresponding to a certain gene in the data matrix using our own Java application MyStats. P values and the differential expression in fold changes for all the probesets were generated as tab-delimited worksheets of Excel for further analysis. The genes were prioritized by ascending p-values. The top 100 probesets were prioritized in both patient datasets, and the genes common to both datasets were analyzed further.

Identification of potential inhibitory compounds targeting TAZ-AXL-CTGF overexpressing colon cancer (Connectivity Map) {#s2e}
----------------------------------------------------------------------------------------------------------------------

Gene expression connectivity mapping was performed using Statistically Significant Connection\'s Map (sscMap) to identify candidate small molecule compounds that may inhibit the expression of genes that are co-regulated in TAZ-AXL-CTGF co-expressing aggressive colon cancer [@pone.0054211-Lamb1], [@pone.0054211-Lamb2], [@pone.0054211-Zhang4]. Of the probesets identified to be co-expressed with TAZ-AXL-CTGF, 33 were present on the Affymetrix HG-U133A microarray platform, which was used to generate the microarray database for the Connectivity Map [@pone.0054211-Lamb1]. The compiled gene signature was then fed to the Java application sscMap [@pone.0054211-Zhang4] as a query signature, and its association with the 6000 gene expression profiles generated by treating cancer cells with over 1000 small molecules were compared. The gene signature perturbation procedure, which increases the specificity of the output results, was applied as previously described [@pone.0054211-McArt1]. All the small molecular compounds, that were negatively associated with the TAZ-AXL-CTGF-GES, were sorted and ranked by their *p*-value, perturbation stability and standardized connection score. The *p*-value that was considered significant was set at a stringent threshold (p = 1/1309), ensuring that the results generated by sccMap yield only maximally one expected false positive small molecule over the 1309 small molecules tested in the sccMap [@pone.0054211-McArt1]. The top 20 small molecules were then entered into the Pubmed ([www.pubmed.com](http://www.pubmed.com)) search engine together with colon cancer to identify research articles that have described their effects of the particular molecules on treatment of colon cancer.

Identification of therapeutic targets for colon cancer patients overexpressing TAZ-AXL-CTGF {#s2f}
-------------------------------------------------------------------------------------------

Patients who co-overexpressed TAZ-AXL-CTGF were stratified into two groups based on their survival statuses. Differential expressions of different probesets between patients in the TAZ-AXL-CTGF-alive subgroup and those in the TAZ-AXL-CTGF-deceased subgroup were identified as described above.

Cell culture and retroviral transduction {#s2g}
----------------------------------------

HCT116 and SW620 cells were obtained from American Type Culture Collection and maintained in F12K/DME medium supplemented with 10% Fetal Bovine Serum (FBS), 10 ug/ml Penicillin/Streptomycin (P/S) (Life technologies, Carlsbad, CA). The amphotropic Phoenix packaging cell line was obtained from the Nolan Laboratory (Stanford University) and maintained in DMEM medium supplemented with 10% FBS and 10 ug/ml P/S. Retroviral infection was performed as previously described [@pone.0054211-Chan2]. The short hairpin (shRNA) against human TAZ construct (5′-AGGTACTTCCTCAATCACA-3′) carried by the pSuperRetro-puro vector (shTAZ) was used for TAZ knockdown (Oligoengine, Seattle, WA) while the scramble shRNA construct (5′-CCTAAGGTTAAGTCGCCCTCG-3′; shScr) was used for control. Stable cell lines were established by selecting the traduced cells in 2 ug/ml puromycin (Sigma Aldrich, St. Louis, MO).

Western blot analysis {#s2h}
---------------------

Immunoblotting was performed as previously described [@pone.0054211-Chan2] using SuperSignal West Pico (Thermo Scientific, Rockford, IL). The commercial TAZ antibody was obtained from Imgenex (San Diego, CA).

Anchorage-independent soft agar and clonogenic assays {#s2i}
-----------------------------------------------------

For the soft agar assay, 5000 cells resuspended in 0.35% (w/v) agarose in culture medium were overlaid on a solidified 0.5% (w/v) agarose in culture medium. The upper layer was allowed to solidify. Medium with puromycin was added the following day and cells were then incubated at 37°^-^C with 5% CO~2~. Fresh medium with puromycin was supplemented and the colonies formed were stained with 1 mg/ml Thiazolyl Blue Tetrazolium Bromide (Sigma Aldrich) for 4 hours in the incubator at 37°C with 5% CO~2~. The excess dye was removed by destaining multiple times with water and the number of colonies was determined.

For clonogenic assay, 500 cells were seeded per well in triplicate in 6-well plate. The culture medium was refreshed every week and the cells were fixed with 4% paraformaldehyde in PBS after 2 weeks incubation at 37°C with 5% CO~2~. The fixed cells were stained with 0.5% crystal violet (Sigma Aldrich) in 20% ethanol overnight. The cells were rinsed with water, dried and colony number was analyzed.

Tumorigenesis in nude mice {#s2j}
--------------------------

Hundred ul of a cell suspension of 1.5×10^7^/ml were inoculated subcutaneously in the left and right hind flanks of four-to-six week-old female nude mice. Tumor development was monitored sfter 2 weeks. Mice were then euthanized and the tumors were removed for analysis.

Results {#s3}
=======

TAZ and YAP mRNA expressions positively correlate with mRNA expression of their downstream target genes, AXL and CTGF {#s3a}
---------------------------------------------------------------------------------------------------------------------

Previously, we and others have shown that *AXL* and *CTGF* are two important downstream target genes of TAZ and YAP [@pone.0054211-Lai1], [@pone.0054211-Xu1], [@pone.0054211-Chan4]. In the present study, we investigated whether the mRNA expression levels of the two transcriptional co-activators in the Hippo pathway, TAZ and YAP, correlate with the mRNA expression of *AXL* and *CTGF*. In the 290 colon cancer patients from the GSE14333 dataset, TAZ expression was significantly correlated with both AXL (Spearman\'s rank test, *r* = 0.547, *p*\<0.001; [Figure 1A](#pone-0054211-g001){ref-type="fig"}) and CTGF (*r* = 0.543, *p*\<0.001; [Figure 1B](#pone-0054211-g001){ref-type="fig"}) expressions. YAP mRNA expression was also positively correlated with AXL (*r* = 0.154, *p* = 0.009; [Figure 1C](#pone-0054211-g001){ref-type="fig"}) and CTGF (*r* = 0.141, *p* = 0.016; [Figure 1D](#pone-0054211-g001){ref-type="fig"}) mRNA expression in the same dataset, but to a lesser extent. In 232 colon cancer patients from GSE17538, TAZ mRNA expression was significantly positively correlated with both AXL (*r* = 0.752, *p*\<0.001; [Figure 1E](#pone-0054211-g001){ref-type="fig"}) and CTGF (*r* = 0.686, *p*\<0.001; [Figure 1F](#pone-0054211-g001){ref-type="fig"}) mRNA expressions, while YAP mRNA was also significantly positively correlated with mRNA expression of both genes, again to a lesser extent (AXL: *r* = 0.343, *p*\<0.001; [Figure 1G](#pone-0054211-g001){ref-type="fig"} and CTGF: *r* = 0.387, *p*\<0.001; [Figure 1H](#pone-0054211-g001){ref-type="fig"}).

![The correlations among mRNA expression of TAZ (WWTR1), YAP (YAP1), AXL and CTGF in colon cancer specimens.\
Scatter plots for (A) TAZ mRNA expression versus *AXL* mRNA expression, (B) TAZ mRNA expression versus *CTGF* mRNA expression, (C) YAP mRNA expression versus *AXL* mRNA expression, and (D) YAP mRNA expression versus *CTGF* mRNA expression in the GSE14333 colon cancer datasets, and (E) TAZ mRNA expression versus *AXL* mRNA expression, (F) TAZ mRNA expression versus *CTGF* mRNA expression, (G) YAP mRNA expression versus *AXL* mRNA expression, and (H) YAP mRNA expression versus *CTGF* mRNA expression in the GSE17538 colon cancer datasets.](pone.0054211.g001){#pone-0054211-g001}

TAZ, but not YAP, mRNA expression is a predictor for patient survival {#s3b}
---------------------------------------------------------------------

In the 226 patients whose survival data were available from the GSE14333 colon cancer patient cohort, a high level of TAZ mRNA expression was significantly correlated with a shorter survival (high level: mean survival = 72.3 months, 95% Confidence Interval (CI) = 63--81 months; low level: mean survival = 129 months, 95% CI = 121--136 months, *p*\<0.001; [Figure 2A](#pone-0054211-g002){ref-type="fig"}). By Cox-regression analysis, TAZ mRNA expression was significantly correlated with survival (Hazards Ratio (HR) = 2.251, 95% CI = 1.626--3.116, *p*\<0.001; [Figure 2C](#pone-0054211-g002){ref-type="fig"}) in the GSE14333 colon cancer patient cohort. By multivariate analysis ([Figure 2C](#pone-0054211-g002){ref-type="fig"}), TAZ mRNA expression (HR = 2.062, 95% CI = 1.472--3.116, *p*\<0.001) and tumor staging (*p*\<0.001) are both independent predictors of survival in the same cohort. Similarly, a high level of TAZ mRNA expression was significantly correlated with shorter patient survival in the GSE17538 colon cancer patient cohort (high level: mean survival = 84 months, 95% CI = 72--96 months; low level: mean survival = 109 months, 95% CI = 97--120 months, *p* = 0.011; [Figure 2B](#pone-0054211-g002){ref-type="fig"}). By Cox-regression, TAZ mRNA expression is a predictor of survival in this cohort (HR = 1.743, 95% CI = 1.177--2.582, *p* = 0.006; [Figure 2D](#pone-0054211-g002){ref-type="fig"}). Mulivariate Cox-regression analysis also showed that TAZ mRNA expression (HR = 1.998, 95% CI = 1.245--3.205, *p* = 0.004; [Figure 2D](#pone-0054211-g002){ref-type="fig"}) was an independent predictor for survival together with stage (*p*\<0.001) and grade (*p* = 0.03) of the cancers in this colon cancer patient cohort. On the other hand, YAP mRNA expression did not significantly correlate with patient survival by Kaplan-Meier analysis (GSE14333: *p* = 0.519; [Figure 2E](#pone-0054211-g002){ref-type="fig"} and GSE17538: *p* = 0.634; [Figure 2F](#pone-0054211-g002){ref-type="fig"}) or by Cox-regression analysis (GSE14333: *p* = 0.673; [Figure 2G](#pone-0054211-g002){ref-type="fig"} and GSE17538: *p* = 0.979; [Figure 3H](#pone-0054211-g003){ref-type="fig"}) in either dataset. These results suggest that TAZ mRNA expression is a novel prognostic marker for colon cancer patients, but YAP is not.

![The associations between TAZ or YAP, and survival in colon cancer patients.\
Kaplan-Meier analyses for TAZ mRNA expression in (A) GSE14333 and (B) GSE17538 colon cancer patient datasets. Univariate and Multivariate Cox regression analyses for TAZ mRNA expression, age, tumor stage and tumor grade in (C) GSE14333 and (D) GSE17538 colon cancer patient datasets. Kaplan-Meier analyses for YAP mRNA expression in (E) GSE14333 and (F) GSE17538 colon cancer patient datasets. Univariate and Multivariate Cox regression analyses for TAZ mRNA expression, age, tumor stage and tumor grade in (G) GSE14333 and (H) GSE17538 colon cancer patient datasets.](pone.0054211.g002){#pone-0054211-g002}

![The associations between AXL or CTGF, and survival in colon cancer patients.\
Kaplan-Meier analyses for *AXL* mRNA expression in (A) GSE14333 and (B) GSE17538 colon cancer patient datasets. Univariate and Multivariate Cox regression analyses for *AXL* mRNA expression, age, tumor stage and tumor grade in (C) GSE14333 and (D) GSE17538 colon cancer patient datasets. Kaplan-Meier analyses for *CTGF* mRNA expression in (E) GSE14333 and (F) GSE17538 colon cancer patient datasets. Univariate and Multivariate Cox regression analyses for *CTGF* mRNA expression, age, tumor stage and tumor grade in (G) GSE14333 and (H) GSE17538 colon cancer patient datasets.](pone.0054211.g003){#pone-0054211-g003}

Both AXL and CTGF, downstream target genes of TAZ and YAP, are predictors of patient survival {#s3c}
---------------------------------------------------------------------------------------------

To investigate whether the functional outcome of the transcriptional program mediated by TAZ and YAP confers prognostic value in colon cancer patients, we analyzed whether the mRNA expression of AXL and CTGF, two of the most well defined target genes of TAZ/YAP-TEAD complexes, correlate with survival of patients in the two colon cancer patient cohorts.

High level mRNA expression of AXL correlated with a shorter colon cancer patient survival time in the GSE14333 cohort, although this correlation was not significant (high level: mean survival = 80 months, 95% CI = 71--88 months; low level: mean survival = 114 months, 95% CI = 101--129 months, *p* = 0.064; [Figure 3A](#pone-0054211-g003){ref-type="fig"}). In the GSE17538 cohort, high level mRNA expression of AXL was significantly correlated with shorter survival (high level: mean survival = 84 months, 95% CI = 72--96 months; low level: mean survival = 104 months, 95% CI = 94--114 months, *p* = 0.004; [Figure 3B](#pone-0054211-g003){ref-type="fig"}). By Cox-regression analysis, AXL mRNA expression was a predictor of patient survival in both the GSE14333 (HR = 1.839, 95% CI = 1.230--2.748, *p* = 0.003; [Figure 3C](#pone-0054211-g003){ref-type="fig"}) and the GSE17538 (HR = 2.158, 95% CI = 1.141--4.081, *p* = 0.018; [Figure 3D](#pone-0054211-g003){ref-type="fig"}) cohorts. In the GSE14333 cohort, AXL mRNA expression (HR = 1.631, 95% CI = 1.076--2.471, *p* = 0.021; [Figure 3C](#pone-0054211-g003){ref-type="fig"}) was an independent predictor of patient survival with tumor staging (*p*\<0.001), while in the GSE17538 cohort, AXL mRNA expression (HR = 3.700, 95% CI = 1.665--8.220, *p* = 0.001; [Figure 3D](#pone-0054211-g003){ref-type="fig"}) was an independent predictor of patient survival together with stage (*p*\<0.001) and grade (*p* = 0.055) of the cancers.

Similar results were obtained for CTGF. A high level of CTGF mRNA expression was significantly correlated with shorter patient survival in both GSE14333 (high level: mean survival = 87 months, 95% CI = 74--102 months; low level: mean survival = 98 months, 95% CI = 88--108 months, *p* = 0.012; [Figure 3E](#pone-0054211-g003){ref-type="fig"}) and GSE17538 (high level: mean survival = 85 months, 95% CI = 73--97 months; low level: mean survival = 105 months, 95% CI = 95--114 months, *p* = 0.004; [Figure 3F](#pone-0054211-g003){ref-type="fig"}) cohorts. Univariate Cox-regression analysis also showed that CTGF mRNA expression was a predictor for patient survival in both cohorts (GSE14333: HR = 1.667, 95% CI = 1.260--2.232, *p*\<0.001; [Figure 3G](#pone-0054211-g003){ref-type="fig"} and GSE17538: HR = 1.433, 95% CI = 1.126--1.825, *p* = 0.004; [Figure 3H](#pone-0054211-g003){ref-type="fig"}). Moreover, CTGF mRNA expression is an independent predictor for survival in both cohorts (GSE14333: HR = 1.543, 95% CI = 1.155--2.061, *p*\<0.001; [Figure 3G](#pone-0054211-g003){ref-type="fig"} and GSE17538: HR = 1.902, 95% CI = 1.385--2.612, *p*\<0.001; [Figure 3H](#pone-0054211-g003){ref-type="fig"}) together with stage (GSE14333: *p*\<0.001 and GSE17538: *p*\<0.001) and grade (GSE17538: *p* = 0.053) of the cancers.

TAZ, AXL and CTGF can be used in combination to predict colon cancer patient survival {#s3d}
-------------------------------------------------------------------------------------

As described above, expression of TAZ, *AXL* and *CTGF* all correlated with colon cancer patient survival. We further investigated whether their expression could be used in combination as a prognostic marker for colon cancer patients. In the GSE14333 cohort, patients whose tumors had low level expression of the three genes had a mean survival time of 117 months (95% CI = 110--123 months), while those whose tumors overexpressed only one of the three genes also had a mean survival of 117 months (95% CI = 101--132 months). Patients whose tumors had a high level expression of two of the three genes had a mean survival time of 65 months (95% CI = 57--74 months), while those whose tumors had a high level expression of all three genes had a mean survival time of 72 months (95% CI = 60--84 months). The survival time of the patients between these four subgroups were significantly different (*p* = 0.001; [Figure 4A](#pone-0054211-g004){ref-type="fig"}). In Cox-regression analysis, using the subgroup containing patients whose tumors had a low expression of all three genes as a reference group, we found that patients whose tumors overexpressed one (HR = 3.953, 95% CI = 1.070--14.607, *p* = 0.039), two (HR = 6.503, 95% CI = 1.894--22.330, *p* = 0.003) or all the three genes (HR = 7.656, 95% CI = 2.287--25.628, *p* = 0.001) had an increasing risk for disease progression ([Figure 4C](#pone-0054211-g004){ref-type="fig"}).

![The associations between TAZ-AXL-CTGF expression and survival in colon cancer patients.\
Patients were divided into 4 groups according to the number of genes that they overexpressed (expressed at above the Median level) among TAZ, *AXL* and *CTGF*. Kaplan-Meier analyses for TAZ-AXL-CTGF mRNA expression in (A) GSE14333 and (B) GSE17538 colon cancer patient datasets. Univariate and Multivariate Cox regression analyses for TAZ-AXL-CTGF mRNA expression, age, tumor stage and tumor grade in (C) GSE14333 and (D) GSE17538 colon cancer patient datasets.](pone.0054211.g004){#pone-0054211-g004}

Similar results were obtained in the GSE17538 patient cohort. Patients whose tumors expressed the three genes at low level had a mean survival time of 108 months (95% CI = 97--119 months), those whose tumors had a high level expression of one of the three genes had a mean survival time of 88 months (95% CI = 72--104 months), those whose tumors overexpressed two of the three genes had a mean survival time of 99 months (95% CI = 78--121 months), while those whose tumors overexpressed all three genes had a mean survival time of 77 months (95% CI = 63--91 months). Increasing incidence of overexpression of these three genes resulted in significantly shorter survival in these patients (Kaplan-Meier analysis, *p* = 0.01; [Figure 4B](#pone-0054211-g004){ref-type="fig"}). Cox-regression analysis using tumors that overexpressed none of the three genes as reference revealed that patients whose tumors overexpressed one (HR = 1.675, 95% CI = 0.75--3.741, *p* = 0.203), two (HR = 1.770, 95% CI = 0.790 = 3.966, *p* = 0.166) and all of the three genes (HR = 2.807, 95% CI = 1.482--5.317, *p* = 0.002) had an increased risk for disease progression ([Figure 4D](#pone-0054211-g004){ref-type="fig"}).

Indeed, patients whose tumors expressed TAZ, *AXL* and *CTGF* mRNA at low levels (GSE14333: mean survival = 117 months, 95% CI = 110--123; GSE17538: mean survival = 108 months, 95% CI = 95--121 months) had superior survival compared to those whose tumors overexpressed all the three genes (GSE14333: mean survival = 96, 95% CI = 84--108, *p*\<0.001; GSE17538: mean survival = 91 months, 95% CI = 81--101 months, *p* = 0.037; [Figure S1](#pone.0054211.s001){ref-type="supplementary-material"}).

Neither the age nor sex of the patients was factor that determined the number of TAZ, AXL and CTGF that overexpressed in either colon cancer patient cohort. TAZ-AXL-CTGF expression was only significantly lower in tumors stage A compared to tumors of other stages (*p* = 0.022), but were not significantly different between other stages in GSE14333. In GSE17538, TAZ-AXL-CTGF expression was not significantly different between AJCC stages or tumor grades. When the patients were stratified by their stage, we found that TAZ-AXL-CTGF expression was still significantly correlated with poor survival in patients with higher stage tumors. In GSE14333, increasing number of genes overexpressed among TAZ, AXL and CTGF was significantly correlated with a shorter survival (HR = 1.414, 95% CI = 1.031--1.938, *p* = 0.032) in patients with stage C tumors. Similar results were obtained in GSE17538, in which, TAZ-AXL-CTGF expression was associated with poorer survival in patients with tumors of higher grade and higher stage. TAZ-AXL-CTGF expression was correlated with poorer survival in both grade B (HR = 1.315, 95% CI = 1.026 = 1.685, *p* = 0.031) and grade C (HR = 1.671, 95% CI = 1.001--2.790, *p* = 0.05) tumors, as well as AJCC stage 3 (HR = 1.694, 95% CI = 1.075--2.670, *p* = 0.023) and stage 4 (HR = 1.415, 95% CI = 1.074--1.866, *p* = 0.014) tumors.

Identification of genes that are differentially expressed between TAZ-AXL-CTGF-high and low patients {#s3e}
----------------------------------------------------------------------------------------------------

We found that 39 genes, including TAZ, AXL and CTGF, were significantly differentially expressed between TAZ-AXL-CTGF-high and low patients in both datasets. Some of these 39 genes have been shown to be induced by overexpressing YAP/TAZ-TEAD complexes in transfected cells [@pone.0054211-Zhang3], [@pone.0054211-Zhao4], including Akt3, CCDC80, FBN1, FRMD6, MSRB3, MYL9, PTRF, TAGLN, TNS1, VCAN and ZEB1 ([Tables 1](#pone-0054211-t001){ref-type="table"} and [2](#pone-0054211-t002){ref-type="table"}). Also co-regulated with TAZ-AXL-CTGF were genes involved in EMT, migration and invasion, colon cancer progression, calcium signaling, angiogenesis, cytoskeleton association, membrane trafficking, focal adhesion, Hippo pathway regulation, and MMPs inhibition ([Tables 1](#pone-0054211-t001){ref-type="table"} and [2](#pone-0054211-t002){ref-type="table"}), suggesting that these biological processes may play an important role in TAZ-AXL-CTGF-mediated colon cancer progression.

10.1371/journal.pone.0054211.t001

###### Genes that are co-regulated with TAZ-AXL-CTGF expression in GSE14333 colon cancer patient cohort.

![](pone.0054211.t001){#pone-0054211-t001-1}

  GSE14333                                Number of TAZ/AXL/CTGF that are overexpressed                                                          
  -------------------------------------- ----------------------------------------------- ---------- ------ ----------- ------ ----------- ------ ------------
  **Epithelial-Mesencymal transition**                                                                                                           
  **ACTA2**                                                    97                         84--111    105     95--114    120    109--132    147     130--164
  **ZEB1**                                                     76                          62--90     92     83--100    112    102--122    163     141--186
  **ZEB2**                                                     21                          19--23     28     25--30      29     27--32      37      34--40
  **Migration and Invasion**                                                                                                                     
  DDR2                                                         95                         73--117    108     99--117    126    113--139    189     161--217
  **FERMT2**                                                   105                        69--140    120    107--132    153    135--171    246     203--288
  **AKT3**                                                     48                          43--52     56     51--60      61     56--65      79      72--85
  **VCAN**                                                     469                        386--552   671    578--764    728    636--820    1275   1103--1447
  **Colon cancer biomarkers**                                                                                                                    
  **EFEMP2**                                                   140                        125--156   184    166--202    208    187--229    300     268--331
  **SULF1**                                                    687                        558--816   1003   867--1139   1126   984--1267   1764   1579--1949
  **TAGLN**                                                    319                        208--430   395    347--443    528    435--621    866    705--1026
  **Calcium binding/signaling**                                                                                                                  
  **FBN1**                                                     156                        125--188   217    184--249    234    209--260    415     352--478
  **CALD1**                                                    84                          73--96     98     89--106    106     98--114    156     135--177
  **MGP**                                                      66                          39--92     84     60--107    106     81--130    301     216--386
  **MYL9**                                                     358                        200--515   419    361--477    613    475--752    1137   904--1371
  **Angiogenesis**                                                                                                                               
  ANTXR1                                                       42                          39--45     50     46--53      51     47--54      62      57--66
  **SERPINF1**                                                 412                        340--485   595    529--662    681    594--768    1038   882--1194
  **Cytoskeleton associated protein**                                                                                                            
  **DPYSL3**                                                   44                          35--53     58     51--65      59     53--65     101     86--117
  **PDLIM3**                                                   38                          28--47     43     39--47      56     50--62      86     73--100
  **Membrane trafficking**                                                                                                                       
  **RAB31**                                                    343                        283--404   489    427--551    556    480--631    786     696--876
  RAB34                                                        88                         69--107    126    112--140    158    137--179    226     200--252
  **Focal adhesion**                                                                                                                             
  **TGFB1I1**                                                  205                        162--249   260    230--289    314    273--354    459     397--521
  **TNS1**                                                     43                          38--48     50     46--54      61     55--66      78      69--87
  **Hippo pathway related genes**                                                                                                                
  AMOTL1                                                       18                          15--22     19     18--21      23     20--25      30      26--33
  FRMD6                                                        130                        104--155   175    153--197    217    188--246    351     300--401
  VGLL3                                                        47                          30--64     56     49--63      71     62--80     107     91--123
  **Tissue inhibitor of MMPs**                                                                                                                   
  TIMP2                                                        279                        234--323   443    393--492    486    433--538    698     632--763
  **TIMP3**                                                    264                        221--307   352    299--404    417    362--471    563     502--624
  **Others**                                                                                                                                     
  CCDC80                                                       53                          31--76     65     57--73      82     71--92     155     128--182
  **COL5A1**                                                   362                        309--416   516    447--586    559    488--630    872     753--991
  **GEM**                                                      361                        267--455   474    418--531    534    484--583    945    800--1090
  GLT8D2                                                       123                        102--144   167    146--187    184    162--205    274     236--311
  MSRB3                                                        86                         59--113    104     94--115    129    112--146    196     167--225
  **NNMT**                                                     330                        265--396   483    414--552    565    473--658    848     731--965
  **NXN**                                                      170                        135--205   260    201--320    274    234--314    360     321--400
  **PTRF**                                                     140                        117--163   170    157--182    189    172--205    272     242--303
  SFRP2                                                        218                        100--337   305    208--402    404    296--511    1142   900--1394

10.1371/journal.pone.0054211.t002

###### Genes that are co-regulated with TAZ-AXL-CTGF expression in GSE17538 colon cancer patient cohort.

![](pone.0054211.t002){#pone-0054211-t002-2}

  GSE17538                                Number of TAZ/AXL/CTGF that are overexpressed                                                            
  -------------------------------------- ----------------------------------------------- ---------- ------ ------------ ------ ------------ ------ ------------
  **Epithelial-Mesencymal transition**                                                                                                             
  ACTA2                                                        175                        165--184   211     198--224    240     228--252    292     269--315
  ZEB1                                                         113                        106--121   152     140--165    185     171--200    262     234--290
  ZEB2                                                         56                          54--59     70      66--75      79      75--84      97     92--101
  **Migration and Invasion**                                                                                                                       
  DDR2                                                         203                        190--216   250     232--268    316     293--339    440     392--487
  FERMT2                                                       133                        121--144   201     179--223    259     232--286    416     357--475
  AKT3                                                         80                          76--84     94     89--100     109     102--116    127     121--133
  VCAN                                                         584                        515--652   945    823--1066    1314   1126--1503   2188   1958--2419
  **Colon cancer biomarkers**                                                                                                                      
  EFEMP2                                                       243                        230--256   310     282--339    403     364--442    513     476--549
  SULF1                                                        726                        633--818   1186   1026--1345   1897   1665--2129   2803   2578--3029
  TAGLN                                                        670                        619--722   855     785--925    1215   1055--1375   1779   1562--1996
  **Calcium binding/signaling**                                                                                                                    
  FBN1                                                         169                        152--185   263     231--295    376     334--418    623     544--702
  CALD1                                                        162                        153--171   201     188--214    234     220--249    303     277--330
  MGP                                                          101                        91--110    151     132--169    207     179--235    381     308--454
  MYL9                                                         448                        398--498   643     568--717    1010   830--1190    1678   1340--2016
  **Angiogenesis**                                                                                                                                 
  ANTXR1                                                       187                        180--194   216     206--226    251     240--261    290     278--302
  SERPINF1                                                     656                        584--728   1106   815--1396    1315   1150--1480   1937   1708--2165
  **Cytoskeleton associated proteins**                                                                                                             
  DPYSL3                                                       135                        125--146   186     168--204    226     204--248    308     280--336
  PDLIM3                                                       68                          65--71     84      80--89      99     94--104     139     118--160
  **Membrane trafficking**                                                                                                                         
  RAB31                                                        501                        443--559   711     619--804    1021   889--1154    1549   1394--1704
  RAB34                                                        227                        208--247   313     253--372    347     317--378    497     452--542
  **Focal adhesion**                                                                                                                               
  TGFB1I1                                                      388                        358--417   465     412--517    672     599--746    880     796--964
  TNS1                                                         157                        149--165   185     175--195    221     208--235    256     244--268
  **Hippo pathway related genes**                                                                                                                  
  AMOTL1                                                       106                        99--114    133     123--143    147     136--157    167     159--175
  FRMD6                                                        202                        179--224   309     265--353    429     369--490    756     659--853
  VGLL3                                                        45                          41--50     67      58--76      91     79--103     153     130--176
  **Tissue inhibitor of MMPs**                                                                                                                     
  TIMP2                                                        706                        641--771   988    882--1094    1372   1254--1489   1814   1690--1939
  TIMP3                                                        485                        431--539   694     620--769    959    838--1080    1389   1269--1508
  **Others**                                                                                                                                       
  CCDC80                                                       121                        112--131   151     137--165    201     182--221    302     262--343
  COL5A1                                                       501                        451--552   699     602--795    1066   929--1204    1525   1364--1690
  GEM                                                          365                        328--401   620     533--708    747     648--846    1177   1049--1305
  GLT8D2                                                       177                        159--195   246     215--276    351     306--395    523     467--579
  MSRB3                                                        175                        165--186   222     208--237    284     258--310    403     359--446
  NNMT                                                         487                        436--539   736     651--822    1074   892--1256    1543   1385--1701
  NXN                                                          283                        258--308   410     348--472    499     440--559    681     613--748
  PTRF                                                         264                        246--282   317     293--341    378     344--411    564     513--615
  SFRP2                                                        331                        210--451   530     383--677    1036   779--1294    2199   1763--2634

Individually, as expected because of their strong association with the TAZ-AXL-CTGF expressions, all of the genes in the list ([Tables 1](#pone-0054211-t001){ref-type="table"} and [2](#pone-0054211-t002){ref-type="table"}) were significantly correlated with patient survival (*p*\<0.05; data not shown). More importantly, we found that although none of the genes on the list were associated with patient survival in the TAZ-AXL-CTGF-high group of patients (data not shown), *MGP*, *PDLIM3*, *TAGLN* and *ZEB2* were predictors of survival in the TAZ-AXL-CTGF-low group of patients, in the combined colon cancer patient cohort ([Figure 5](#pone-0054211-g005){ref-type="fig"}). When the two colon cancer patient datasets were combined, as expected, TAZ-AXL-CTGF mRNA expression levels were associated with patient survival (*p*\<0.001; [Figure 5A](#pone-0054211-g005){ref-type="fig"}). A high level of *MGP* (*p* = 0.01; [Figure 5B](#pone-0054211-g005){ref-type="fig"}), *PDLIM3* (*p* = 0.037; [Figure 5C](#pone-0054211-g005){ref-type="fig"}), *TAGLN* (*p* = 0.044; [Figure 5D](#pone-0054211-g005){ref-type="fig"}) and *ZEB2* (*p* = 0.038; [Figure 5E](#pone-0054211-g005){ref-type="fig"}) mRNA expression were correlated with a shorter survival time in the TAZ-AXL-CTGF-low group of patients. These results suggest that these four genes may be used as prognostic markers for patients who express low levels of TAZ, *AXL* and *CTGF* mRNA.

![Kaplan-Meier analyses for the mRNA expression of TAZ-AXL-CTGF and its co-regulated genes in the combined colon cancer dataset.\
(A) Kaplan-Meier analysis for TAZ-AXL-CTGF mRNA expression in the combined colon cancer datasets. Kaplan-Meier analyses for mRNA expression of (B) MGP, (C), PDLIM3, (D) TAGLN and (E) ZEB2 in colon cancer patients expressing low levels of TAZ-AXL-CTGF (blue line in (A)) in the combined colon cancer datasets.](pone.0054211.g005){#pone-0054211-g005}

Identification of potential small molecules that could target the 39 gene signature of TAZ-AXL-CTGF co-expression {#s3f}
-----------------------------------------------------------------------------------------------------------------

Analysis to determine alterations in gene expression following small molecule treatment of cancer cells revealed a total of 257 small molecules that were associated with a gene expression signature significantly correlated with the TAZ-AXL-CTGF gene expression signature (the 25 genes that are presented in bold in [Tables 1](#pone-0054211-t001){ref-type="table"} and [2](#pone-0054211-t002){ref-type="table"} together with TAZ, AXL and CTGF). Of the 257 small molecules, 164 had a 100% perturbation stability and 138 of them are inversely correlated with the TAZ-AXL-CTGF gene expression signature. The results are listed in the supplementary information. The top 20 small molecules were further analyzed through a Pubmed search regarding their effects on treatment of colon cancer. We found that amiloride and tretinoin have yielded 55 and 123 publications, respectively, when coupled with colon cancer in the search engine. Several publications have shown their inhibitory effect on colon cancer growth. Amiloride treatment has been shown to inhibit the growth of colon cancer cells *in vitro* [@pone.0054211-SzolgayDaniel1] and *in vivo* [@pone.0054211-Tatsuta1]. Importantly, it can sensitize doxorubicin resistant colon cancer cells to treatment with doxorubicin [@pone.0054211-Pannocchia1], suggesting that amiloride and doxorubicin can be combined to treat doxorubicin resistant colon cancer. Tretinoin, also known as all-trans retinoic acid, has been shown to inhibit proliferation and anchorage-independent growth of colon cancer cells *in vitro* [@pone.0054211-Hoosein1], [@pone.0054211-Kim1] and *in vivo* [@pone.0054211-Narahara1], probably through regulating the differentiation state of cancer cells [@pone.0054211-Rai1].

Identification of potential therapeutic targets for patients overexpressing TAZ-AXL-CTGF {#s3g}
----------------------------------------------------------------------------------------

We further investigated which genes could be used to further predict survival in TAZ-AXL-CTGF-high patients; these genes may be potential therapeutic targets specific for this group of patients whose colon cancers are more aggressive. Therefore, we compared gene expression in this group of patients between those patients who were still living and those who were deceased. The two cohorts\' top 100 differentially expressed genes (based on survival status) were compared, revealing that *ANO1* and *SQLE* are the two genes commonly differentially expressed between those TAZ-AXL-CTGF-high colon cancer patients who are still alive and those who are deceased. By Kaplan-Meier analysis, we found that these two genes themselves were associated with patient survival in both colon cancer datasets ([Figure S2](#pone.0054211.s002){ref-type="supplementary-material"}). We then investigated whether the associations between *ANO1* or *SQLE* and patient survival were specific to patients who overexpressed TAZ, *AXL* and *CTGF* (i.e. the TAZ-AXL-CTGF-high subgroup). A low level of *ANO1* expression was significantly (GSE14333, *p* = 0.002; [Figure 6D](#pone-0054211-g006){ref-type="fig"} and GSE17538, *p* = 0.007; [Figure 6L](#pone-0054211-g006){ref-type="fig"}) associated with better survival in TAZ-AXL-CTGF-high patients in both colon cancer datasets (GSE1433: high level, mean survival = 59 months, 95% CI = 44--73 months, vs. low level, mean survival = 100 months, 95% CI = 86--114 months; GSE17538: high level, mean survival = 66 months, 95% CI = 51--82 months, vs. low level, mean survival = 107 months, 95% CI = 87--127 months), but was not associated with survival in patients with other patterns of expression for TAZ-AXL-CTGF ([Figure 6A, B, C, I, J, K](#pone-0054211-g006){ref-type="fig"}). Similarly, a low level of *SQLE* expression was significantly (GSE14333, *p* = 0.02; [Figure 6H](#pone-0054211-g006){ref-type="fig"} and GSE17538, *p* = 0.01; [Figure 6P](#pone-0054211-g006){ref-type="fig"}) associated with better survival for TAZ-AXL-CTGF-high patients in both colon cancer datasets (GSE1433: high level, mean survival = 55 months, 95% CI = 40--70 months, vs. low level, mean survival = 88 months, 95% CI = 73--103 months; GSE17538: high level, mean survival = 62 months, 95% CI = 45--79 months, vs. low level, mean survival = 86 months, 95% CI = 71--101 months), but was not or less significant in patients with other patterns of expression for TAZ-AXL-CTGF ([Figure 6E, F, G, M, N, O](#pone-0054211-g006){ref-type="fig"}). When both *ANO1* and *SQLE* genes were included in multivariate Cox-regression analysis, we found that mRNA expression of *ANO1*, but not *SQLE*, was an independent predictor of patient survival together with both tumor stage and TAZ-AXL-CTGF expression in both colon cancer patient datasets ([Tables 3](#pone-0054211-t003){ref-type="table"} and [4](#pone-0054211-t004){ref-type="table"}). These results suggest that *ANO1* and *SQLE* mRNA expression may determine the aggressiveness of TAZ-AXL-CTGF-high tumors and that *ANO1* mRNA expression could be used in combination with TAZ-AXL-CTGF and tumor stage for better prognostification. Our results also imply that blockade of *ANO1* or *SQLE* mRNA expression or inhibition of these two proteins in this group of patients may prolong survival.

![The prognostic significance of *ANO1* and *SQLE* mRNA expression in colon cancer patients stratified by their TAZ-AXL-CTGF mRNA expression.\
Kaplan-Meier analyses for *ANO1* mRNA expression in patients overexpressing (A) none, (B) one, (C) two and (D) three of the three genes (TAZ, *AXL* and *CTGF*) in the GSE14333 colon cancer patient datasets. Kaplan-Meier analyses for *SQLE* mRNA expression in patients overexpressing (E) none, (F) one, (G) two and (H) three of the three genes in the GSE14333 colon cancer patient datasets. Kaplan-Meier analyses for *ANO1* mRNA expression in patients overexpressing (I) none, (J) one, (K) two and (L) three of the three genes in the GSE17538 colon cancer patient datasets. Kaplan-Meier analyses for *SQLE* mRNA expression in patients overexpressed in the GSE17538 colon cancer patient datasets.](pone.0054211.g006){#pone-0054211-g006}

10.1371/journal.pone.0054211.t003

###### Cox-regression analysis of GSE14333 datasets.

![](pone.0054211.t003){#pone-0054211-t003-3}

  Clinicopathological variables       Multivariate analysis (Forward conditional)  
  ---------------------------------- --------------------------------------------- -----------
  Stage (n = 226)                                       Overall                     **0.001**
  A (n = 41)                                               1                        Reference
  B (n = 94)                                     2.648 (0.592--11.843)                0.203
  C (n = 91)                                     7.213 (1.688--30.817)              **0.008**
  Hippo pathway activity (n = 226)                                                    0.086
  0 gene overexpressed (n = 59)                            1                        Reference
  1 gene overexpressed (n = 52)                  3.798 (1.009--14.302)              **0.049**
  2 genes overexpressed (n = 54)                 4.961 (1.428--17.236)              **0.012**
  3 genes overexpressed (n = 61)                 4.505 (1.310--15.492)              **0.017**
  *ANO1* (n = 226)                               1.550 (1.161--2.069)               **0.003**

10.1371/journal.pone.0054211.t004

###### Cox-regression analysis of GSE17538 datasets.

![](pone.0054211.t004){#pone-0054211-t004-4}

  Clinicopathological variables       Multivariate analysis (Forward conditional)  
  ---------------------------------- --------------------------------------------- -------------
  Age (n = 213)                                  1.024 (1.002--1.046)                **0.029**
  Stage (n = 213)                                       Overall                     **\<0.001**
  1 (n = 27)                                               1                         Reference
  2 (n = 65)                                     4.089 (0.513--32.586)                 0.184
  3 (n = 70)                                     6.898 (0.887--53.641)                 0.065
  4 (n = 51)                                   79.966 (10.374--616.406)             **\<0.001**
  Hippo pathway activity (n = 213)                                                   **0.013**
  0 gene overexpressed (n = 64)                            1                         Reference
  1 gene overexpressed (n = 38)                  1.106 (0.439--2.787)                  0.830
  2 genes overexpressed (n = 34)                 1.050 (0.410--2.691)                  0.920
  3 genes overexpressed (n = 77)                 2.784 (1.208--6.419)                **0.016**
  ANO1 (n = 213)                                 1.855 (1.286--2.677)                **0.001**

The role of TAZ in colon cancer progression in vitro and in vivo {#s3h}
----------------------------------------------------------------

To confirm the bioinformatics analysis, we investigated the effect of TAZ knockdown in two colon cancer cell lines, HCT116 and SW620. TAZ knockdown in these two cell lines abolished the expression of TAZ and down-regulated AXL expression ([Figure 7A](#pone-0054211-g007){ref-type="fig"}). This result is in line with our finding in human specimens showing that AXL is a downstream target of TAZ. Knockdown of TAZ also resulted in a significant reduction in the number of colonies formed in both clonogenic and non-adherent soft-agar assays in these two cell lines ([Figure 7B and C](#pone-0054211-g007){ref-type="fig"}). Importantly, these *in vitro* results were replicated in *in vivo* tumorigenesis assay. Both HCT116-shTAZ and SW620-shTAZ cells formed significantly larger tumors in nude mice compared to HCT116-shScr and SW620-shScr cells, respectively ([Figure 7D and 7E](#pone-0054211-g007){ref-type="fig"}, respectively). Our results suggest that TAZ expression is required for a higher cell proliferation, non-adherent growth and tumorigenesis in colon cancer cells, traits that are associated with colon cancer progression.

![In vitro and in vivo assays for colon cancer cells expressing scramble shRNA or TAZ shRNA.\
(A) Western blot showing that shTAZ specifically knockdown TAZ, but not YAP, and that AXL was down-regulated in shTAZ cells compared to shScr cells. (B) The clonogenicity and non-adherent growth of HCT116 cells expressing shScr or shTAZ were assessed and the number of colonies formed from three repeats was recorded (C) The clonogenicity and non-adherent growth of SW620 cells expressing shScr or shTAZ were assessed and the number of colonies formed from three repeats was recorded. (D) The in vivo tumorigenicity of HCT116 cells expressing shScr or shTAZ was assessed in nude nice, and the tumor formed was excised and weighted (n = 3 in each group). (E) The in vivo tumorigenicity of SW620 cells expressing shScr or shTAZ was assessed in nude nice, and the tumor formed was excised and weighted (n = 3 in each group).](pone.0054211.g007){#pone-0054211-g007}

Discussion {#s4}
==========

In the present study, we have shown that TAZ mRNA expression is positively correlated with two of its downstream targets, *AXL* and *CTGF*, and that TAZ is significantly associated with poor survival of colon cancer patients in two independent colon cancer datasets, comprising 522 patients. Interestingly, the upregulation of *AXL* and *CTGF*, which reflects the increased transcriptional activity of TAZ-TEAD complexes, can be used in combination with TAZ mRNA expression, for better prognostification in these two independent colon cancer patient datasets. Genes that are co-regulated with TAZ-AXL-CTGF overexpression are involved in several important cellular processes, including cell migration, angiogenesis and calcium signaling, as well as others that have already been described as prognostic markers for colon cancer progression. These genes may be upstream factors or downstream effectors of TAZ and the dysregulated Hippo pathway in colon cancers. Importantly, we also identified two potential therapeutic targets, *ANO1* and *SQLE*, for patients with upregulated TAZ-AXL-CTGF expression; downregulation of either of these two genes may greatly improve the survival of TAZ-AXL-CTGF-high colon cancer patients.

An increase in TAZ mRNA may not necessarily correlate with an increase of its transcriptional activity, due to the fact that TAZ could be post-translationally regulated via cytoplasmic sequestration by 14-3-3 [@pone.0054211-Chan1]. Possible disparity between TAZ mRNA expression and its transcriptional activity may impair the lone utilization of TAZ mRNA expression as a prognostic marker. Previously, we have shown that *AXL* [@pone.0054211-Xu1] and *CTGF* [@pone.0054211-Chan4] are both downstream targets of the Hippo pathway. In the present study, we have analyzed the transcriptional outcome of TAZ-TEAD complexes in colon cancer using AXL or CTGF alone or in combination with TAZ and found that patients who co-overexpressed all three genes had significantly poorer survival compared to those who had other expression patterns. Our results, therefore, strongly suggest that TAZ, *AXL* and *CTGF* can be used in combination for prognostification in colon cancer patients.

Several genes that are related to EMT are overexpressed in high TAZ-AXL-CTGF expressing patients ([Tables 1](#pone-0054211-t001){ref-type="table"} and [2](#pone-0054211-t002){ref-type="table"}). These include *ACTA2* [@pone.0054211-Kalluri1], *ZEB1* [@pone.0054211-Spaderna1], [@pone.0054211-Wellner1] and *ZEB2* [@pone.0054211-Beltran1], [@pone.0054211-Kahlert1]. Interestingly, *ZEB1* has been shown to be a downstream target of TAZ in retinal pigment epithelial cells [@pone.0054211-Liu2], suggesting that *ZEB1* may act as a downstream effector of TAZ to promote cancer metastasis, while *ZEB1* and *ZEB2* have also been shown to be prognostic markers in colon cancer [@pone.0054211-Spaderna1], [@pone.0054211-Kahlert1]. Genes that govern migration and invasion were also differentially expressed ([Tables 1](#pone-0054211-t001){ref-type="table"} and [2](#pone-0054211-t002){ref-type="table"}). *AKT3*, which has been shown to contribute oncogenic functions similar to other AKT isoforms [@pone.0054211-Mende1], was up-regulated in the TAZ-AXL-CTGF-high group of patients. *DDR2* [@pone.0054211-Labrador1], [@pone.0054211-Olaso1], *FERMT2* [@pone.0054211-Montanez1], [@pone.0054211-Tu1], [@pone.0054211-Shen1] and *VCAN* [@pone.0054211-Said1] also play significant roles in cell adhesion and migration and are upregulated in TAZ-AXL-CTGF-high group of patients.

Colon cancer biomarkers were also differentially expressed in these two groups of patients ([Tables 1](#pone-0054211-t001){ref-type="table"} and [2](#pone-0054211-t002){ref-type="table"}), namely *EFEMP2*, a serum biomarker for early detection of colon cancer [@pone.0054211-Yao1] and *SULF1*, a protein important in colon cancer diagnosis [@pone.0054211-Babel1] and whose serum level is elevated in patients with colon adenomas [@pone.0054211-Matusiewicz1]. Genes that are implicated in angiogenesis were also identified ([Tables 1](#pone-0054211-t001){ref-type="table"} and [2](#pone-0054211-t002){ref-type="table"}); both *VCAN* [@pone.0054211-Koyama1], [@pone.0054211-Zheng1] and *ANTXR1* [@pone.0054211-Chaudhary1], [@pone.0054211-Fernando1], [@pone.0054211-Duan1] promote angiogenesis for cancer progression. Four genes that are involved in calcium binding or signaling were co-regulated with TAZ-AXL-CTGF in the colon cancer specimens, including *FBN1* [@pone.0054211-Kettle1], *CALD1* [@pone.0054211-Mayanagi1], *MGP* [@pone.0054211-FarzanehFar1] and *MYL9* [@pone.0054211-SzczesnaCordary1].

Interestingly, genes that play a role in regulating the Hippo pathway were also co-regulated with TAZ-AXL-CTGF. The angiomotin family members act as tumor suppressors by inhibiting the oncogenic functions of YAP and TAZ [@pone.0054211-Chan4], [@pone.0054211-Zhao5], while *FRMD6* also acts as an antagonist of YAP by activating Hippo pathway kinases [@pone.0054211-Angus1]. In this study, we found that *AMOLT1* and *FRMD6* are co-overexpressed in TAZ-AXL-CTGF positive tumors, suggesting that *AMOLT1* and *FRMD6* may form a negative regulatory loop with TAZ activation, which requires further investigation *in vitro* in colon cancer cell line models. In addition, VGLL3, which has been shown to act as a co-activator of TEAD transcription factors is also upregulated in TAZ-AXL-CTGF-high tumors [@pone.0054211-HeliasRodzewicz1].

Treatments targeting TAZ-AXL-CTGF-high cancers are required due to the aggressive nature of this type of colon cancer. We employed two different analyses to identify potential therapeutic agents and gene targets for this type of cancer. In sccMap, we found that amiloride and tretinoin may inhibit the gene expression signature associated with this aggressive type of colon cancer; these molecules have been shown in the literature to provide strong inhibitory effects on colon cancer proliferation *in vitro* and *in vivo*. The other 18 small molecules of the top twenty identified by sccMap as listed in the supplementary information have yet to be studied in term of their effect on colon cancer progression driven by the overexpression of TAZ-AXL-CTGF co-overexpression.

*ANO1*, also named DOG1, has been shown to be ubiquitously expressed in gastrointestinal stromal tumors [@pone.0054211-West1] and its overexpression is correlated with development of distant metastases in head and neck squamous cell carcinoma [@pone.0054211-Ayoub1]. Recently, *ANO1* was shown to promote tumorigenesis and cancer progression via activating MAPK [@pone.0054211-Duvvuri1]. In the same study, the authors demonstrated that pharmacological inhibition of *ANO1* resulted in cancer cell death, however the role of *ANO1* in colon cancer progression has not been examined. In the present study, we found that a low level expression of *ANO1* in the aggressive TAZ-AXL-CTGF-high subgroup of colon cancer patients is associated with prolonged survival (high level to low level of *ANO1* expression; mean survival from 59 to 100 months and from 66 to 107 month in GSE14333 and GSE17538 patient datasets, respectively), suggesting that pharmacological inhibition of *ANO1* may represent a novel therapeutic approach for this group of patients with aggressive colon cancer. *ANO1* is a calcium ion-activated chloride channel. Interestingly, multiple genes involved in calcium signaling (*FBN1*, *CALD1*, *MGP* and *MYL9*) were co-overexpressed with TAZ-AXL-CTGF in colon cancer. Due to the fact that calcium signaling plays an important role in cancer progression [@pone.0054211-Clapham1], [@pone.0054211-Monteith1], [@pone.0054211-Prevarskaya1], further investigation into the relationship between *ANO1* and calcium signaling in TAZ-AXL-CTGF-mediated cancer progression is warranted. Nonetheless, our results provide a clue to the involvement of calcium signaling and Ca^2+^-activated CI^−^ channels in colon cancer progression mediated by the Hippo pathway.

Little is known about how *SQLE* promotes cancer progression. It has been shown to be overexpressed in lung squamous cell carcinoma by suppression subtractive hydridization [@pone.0054211-Liu3], in pancreatic cancer by genome-wide analysis using microarray based techniques [@pone.0054211-Harada1], and in prostate cancer progression by bioinformatics analysis [@pone.0054211-Zhao6]. Its overexpression in breast cancer is correlated with decreased distant metastasis-free survival [@pone.0054211-Helms1]. These results show that *SQLE* promotes cancer progression in multiple types of cancer. Again, its role in colon cancer progression was undefined. In the present study, we also found that a high level expression of *SQLE* is associated with poorer survival in TAZ-AXL-CTGF-high patients to be associated with poorer survival (high level to low level of SQLE expression; mean survival from 55 to 88 months and from 62 to 102 month in GSE14333 and GSE17538 patient datasets, respectively), suggesting that SQLE may be a novel therapeutic target for this group of patients.

In conclusion, this study has shown that TAZ-AXL-CTGF in combination may be a novel prognostic indicator for colon cancer progression, and that their overexpression is associated with increased expression of genes that are associated with colon cancer progression. Furthermore, *ANO1* and *SQLE* overexpression may further define a poorer prognosis for colon cancer patients overexpressing TAZ-AXL-CTGF.
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###### 

**Colon cancer patients expressing low levels of TAZ, AXL and CTGF had superior survival.** Patients were stratified into two groups; those whose tumors expressed TAZ, AXL and CTGF mRNA at low level (solid line) and those whose tumors expressed at least one of TAZ, AXL and CTGF at high level (dotted line). Kaplan-Meier analyses for these two subgroups of patients in (A) GSE14333 and (B) GSE17538 colon cancer datasets.

(TIF)

###### 

Click here for additional data file.

###### 

**The associations between ANO1 or SQLE, and survival in colon cancer patients.** Kaplan-Meier analyses for (A) *ANO1* and (B) *SQLE* mRNA expression in the GSE14333 colon cancer patient dataset. Kaplan-Meier analyses for (C) *ANO1* and (D) *SQLE* mRNA expression in the GSE17538 colon cancer patient dataset.

(TIF)

###### 

Click here for additional data file.
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